$CLRB
Cellectar Biosciences, Inc.

2018 Q3 Form 10-Q Financial Statement

#000114420418043453 Filed on August 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.090M $1.180M $1.040M
YoY Change -5.22% 13.46% -24.09%
% of Gross Profit
Research & Development $1.996M $1.723M $2.176M
YoY Change -14.47% -20.81% 124.32%
% of Gross Profit
Depreciation & Amortization $20.00K $10.00K $100.0K
YoY Change -80.0% -90.0% 11.11%
% of Gross Profit
Operating Expenses $1.996M $1.723M $2.176M
YoY Change -14.47% -20.81% -6.61%
Operating Profit -$3.087M -$2.905M -$3.216M
YoY Change -11.37% -9.69%
Interest Expense $6.558K $4.228K $4.941K
YoY Change 65.23% -14.43% 201.83%
% of Operating Profit
Other Income/Expense, Net $72.56K -$15.77K $94.94K
YoY Change 455.19% -116.61% -52.53%
Pretax Income -$3.010M -$2.920M -$3.120M
YoY Change -13.26% -6.41% 46.48%
Income Tax
% Of Pretax Income
Net Earnings -$3.015M -$2.921M -$3.122M
YoY Change -13.13% -6.43% 46.35%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$946.5K -$1.688M -$2.311M
COMMON SHARES
Basic Shares Outstanding 3.595M shares 13.46M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.37M $4.180M $8.310M
YoY Change 189.22% -49.7% 4.92%
Cash & Equivalents $16.37M $4.181M $8.368M
Short-Term Investments
Other Short-Term Assets $750.0K $840.0K $1.030M
YoY Change -27.18% -18.45% 368.18%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.11M $5.016M $9.340M
YoY Change 155.82% -46.29% 14.74%
LONG-TERM ASSETS
Property, Plant & Equipment $192.0K $212.0K $1.580M
YoY Change -87.2% -86.58% 1.94%
Goodwill $1.675M $1.675M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.09K $93.09K $10.00K
YoY Change 80.86% 830.86% 0.0%
Total Long-Term Assets $2.426M $1.981M $3.260M
YoY Change -23.7% -39.25% 0.62%
TOTAL ASSETS
Total Short-Term Assets $17.11M $5.016M $9.340M
Total Long-Term Assets $2.426M $1.981M $3.260M
Total Assets $19.54M $6.997M $12.60M
YoY Change 97.98% -44.47% 10.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.570M $2.090M $1.470M
YoY Change 27.23% 42.18% 79.27%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $2.661M $2.289M $1.590M
YoY Change 24.91% 43.98% 14.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $140.0K
YoY Change -6.67%
Total Long-Term Liabilities $0.00 $568.00 $140.0K
YoY Change -100.0% -99.59% -12.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.661M $2.289M $1.590M
Total Long-Term Liabilities $0.00 $568.00 $140.0K
Total Liabilities $2.661M $2.290M $1.740M
YoY Change 16.69% 31.6% 12.26%
SHAREHOLDERS EQUITY
Retained Earnings -$93.76M -$90.75M
YoY Change 16.81%
Common Stock $43.00 $17.00
YoY Change -68.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.88M $4.707M $10.86M
YoY Change
Total Liabilities & Shareholders Equity $19.54M $6.997M $12.60M
YoY Change 97.95% -44.47% 10.72%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$3.015M -$2.921M -$3.122M
YoY Change -13.13% -6.43% 46.35%
Depreciation, Depletion And Amortization $20.00K $10.00K $100.0K
YoY Change -80.0% -90.0% 11.11%
Cash From Operating Activities -$2.970M -$2.550M -$2.660M
YoY Change 16.93% -4.14% 40.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$250.0K
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $50.00K
YoY Change
Cash From Investing Activities $40.00K $0.00 -$250.0K
YoY Change -233.33% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.11M -90.00K -10.00K
YoY Change -18987.5% 800.0% -100.13%
NET CHANGE
Cash From Operating Activities -2.970M -2.550M -2.660M
Cash From Investing Activities 40.00K 0.000 -250.0K
Cash From Financing Activities 15.11M -90.00K -10.00K
Net Change In Cash 12.18M -2.640M -2.920M
YoY Change -559.62% -9.59% -148.5%
FREE CASH FLOW
Cash From Operating Activities -$2.970M -$2.550M -$2.660M
Capital Expenditures $0.00 $0.00 -$250.0K
Free Cash Flow -$2.970M -$2.550M -$2.410M
YoY Change 18.33% 5.81% 26.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
53172 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
8000 shares
us-gaap Net Income Loss
NetIncomeLoss
-6396514 USD
us-gaap Net Income Loss
NetIncomeLoss
-6012853 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3802955 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4032810 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1723087 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2175929 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1181832 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1040540 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2555491 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1995896 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4180744 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10006421 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1550 shares
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2096 shares
CY2017Q4 us-gaap Assets Current
AssetsCurrent
10939417 USD
CY2018Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
49425 shares
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
53306 shares
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
211970 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
244713 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-46950 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
7525 USD
CY2018Q2 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-20000 USD
CY2017Q2 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
90000 USD
CY2018Q2 clrb Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Unvested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedOutstandingNumber
25395 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Cellectar Biosciences, Inc.
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
34168 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
188325 USD
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000 USD
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
us-gaap Costs And Expenses
CostsAndExpenses
6358446 USD
us-gaap Costs And Expenses
CostsAndExpenses
6028706 USD
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
2904919 USD
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
3216469 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2904919 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3216469 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6358446 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6028706 USD
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2018Q2 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
CY2017Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
780559 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
877996 USD
us-gaap Share Based Compensation
ShareBasedCompensation
349017 USD
us-gaap Share Based Compensation
ShareBasedCompensation
396760 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
57526 shares
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
32131 shares
CY2018Q2 us-gaap Share Based Compensation
ShareBasedCompensation
175579 USD
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
231086 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-46950 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
7525 USD
CY2018Q2 us-gaap Assets Current
AssetsCurrent
5016303 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
65.50
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
225888 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
49864 USD
CY2018Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4228 USD
CY2017Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4941 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8882 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8328 USD
CY2018Q2 us-gaap Goodwill
Goodwill
1675462 USD
CY2017Q4 us-gaap Goodwill
Goodwill
1675462 USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
93086 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11872 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-38068 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15853 USD
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15772 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
94941 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-190575 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
263169 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.70
dei Entity Central Index Key
EntityCentralIndexKey
0001279704
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
349.20
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
179720 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
2432 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2920691 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-3121528 USD
CY2018Q2 us-gaap Assets
Assets
6996821 USD
CY2017Q4 us-gaap Assets
Assets
12871464 USD
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1774992 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1666144 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1774992 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1666144 shares
CY2018Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
152000 USD
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
105050 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.75
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.72
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.69
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.32
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5729636 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5651030 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
19.30
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
CLRB
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
8000 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1731561 shares
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1346199 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1706278 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1274014 shares
CY2018Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2093646 USD
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1867758 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
337000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1425 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
320510 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
72.90
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3595325 shares
CY2018Q2 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedExercisableWeightedAverageExercisePrice
25.70
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1425 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-320510 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
484000 USD
CY2018Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3203 USD
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3036 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
97000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y9M25D
clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm
P8Y8M23D
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Four
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearFour
7000 USD
CY2018Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
40438 USD
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
138944 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
86591 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2289287 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2114788 USD
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2940759 USD
CY2018Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
925000 USD
CY2018Q2 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue
0 USD
CY2018Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1178747 shares
clrb Proceeds From Deferred Issuance Costs
ProceedsFromDeferredIssuanceCosts
-93138 USD
clrb Proceeds From Deferred Issuance Costs
ProceedsFromDeferredIssuanceCosts
-12847 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1478 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1327 USD
CY2018Q2 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
568 USD
CY2017Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
2213 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
57.70
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
21.00 shares
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5825677 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3131546 USD
CY2018Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
568 USD
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2213 USD
CY2018Q2 us-gaap Liabilities
Liabilities
2289855 USD
CY2017Q4 us-gaap Liabilities
Liabilities
2117001 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10061421 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11499619 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4235744 USD
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8368073 USD
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
995782 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Interest Paid Net
InterestPaidNet
364 USD
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
17 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
16 USD
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
95452779 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
94107981 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90745830 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84349316 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
4706966 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
10754463 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6996821 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12871464 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-94616 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2839994 USD
CY2018Q2 us-gaap Area Of Land
AreaOfLand
3983 sqft
CY2018Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P64M
CY2018Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Company also has an option to extend the term of the lease for one additional 60-month period
CY2018Q2 clrb Proceeds To Be Received For Tenant Improvements
ProceedsToBeReceivedForTenantImprovements
179235 USD
clrb Payments For Leases Security Deposits
PaymentsForLeasesSecurityDeposits
75000 USD
CY2018Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
828000 USD
CY2018Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
783000 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4180744 USD
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000 USD
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
780559 USD
CY2018Q2 us-gaap Assets Current
AssetsCurrent
5016303 USD
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
211970 USD
CY2018Q2 us-gaap Goodwill
Goodwill
1675462 USD
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
93086 USD
CY2018Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2093646 USD
CY2018Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
152000 USD
CY2018Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3203 USD
CY2018Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
40438 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2289287 USD
CY2018Q2 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
568 USD
CY2018Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
568 USD
CY2018Q2 us-gaap Liabilities
Liabilities
2289855 USD
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
17 USD
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
95452779 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90745830 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
4706966 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6996821 USD
CY2018Q2 us-gaap Assets
Assets
6996821 USD
CY2018Q3 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2023-07-31

Files In Submission

Name View Source Status
0001144204-18-043453-index-headers.html Edgar Link pending
0001144204-18-043453-index.html Edgar Link pending
0001144204-18-043453.txt Edgar Link pending
0001144204-18-043453-xbrl.zip Edgar Link pending
clrb-20180630.xml Edgar Link completed
clrb-20180630.xsd Edgar Link pending
clrb-20180630_cal.xml Edgar Link unprocessable
clrb-20180630_def.xml Edgar Link unprocessable
clrb-20180630_lab.xml Edgar Link unprocessable
clrb-20180630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv499896_10q.htm Edgar Link pending
tv499896_ex31-1.htm Edgar Link pending
tv499896_ex31-2.htm Edgar Link pending
tv499896_ex32-1.htm Edgar Link pending